

EURORDIS

SYNTHESIS of NATIONAL WORKSHOPS

Denmark - Germany - France - Italy - Spain - Sweden - UK - Netherlands- Portugal -Belgium

> Terkel Andersen Project Manager June 8, 2001



SYNTHESIS

- > Global overview of results:
 - Split Europe/National
 - ♦ Split total « voice »
- > Analysis by themes
- > Questions / discussion



Analysis of European Recommendations

Rank	Proposals	Total	DK	FR	GE	IT	SP	SW	UK
1	Make an inventory of orphan medicinal products & make them available to patients	6		Χ	Χ	Χ	Χ	Χ	Χ
	in all member states - Develop European Data base								
2	Provide information about new drugs,new methods of treatment, clinical trials equally	4	Χ	Χ	Χ		Χ		
	in all countries								
3	List of molecules abandoned by Pharmaceutical industries before development and	3		Χ			Χ	Χ	
	possible withdraw of products developed for common diseases but efficient for RD,								
3	Develop epidemiological studies on RD, data base on RD	3		Χ	Χ				Χ
3	Develop specific clinical trials methodology and "Fast-track" process	3		Χ	Χ	Χ			
4	Join orphan drugs task force regrouping associations, industry, Researcher, GP	2		Χ	Χ				
4	Adoption of normative, economic and insurance tools to get quick access of	2				Χ	Χ		
	new orphan drugs in all member states								
4	Create a European day on RD	2		Χ		Χ			
4	Inform patients on safety of clinical trials and need to create a patient registry	2		Χ			Χ		
5	Create an orphan Drug economic committee managed by EMEA	1		Χ					
5	Improve procedures of recruitment of patients	1				Χ			
5	Establish "Care Standards and Guidelines" for therapy in collaboration with patients	1			Χ				
5	Set up a european network of DNA and tissues banks	1		Χ					
5	Develop a European policy on Rare Diseases together with EMEA	1		Χ					
5	Pharmacovigilance -side effects of Medicinal products	1			Χ				
	Island the handran at many and an extensive to the form t	A	1/						



Analysis of National Recommendations

Rank	Proposals	Total	DK	FR	GE	IT	SP	SW	UK
1	Identify specific incentives and national funds for research on RD, to implement the	5	Χ		Х	Χ	Х		Χ
	Regulation on Orphan Medicinal Products and promote research								
2	Centers of competence aiming at care and treatment - Standard & guidelines therapy	4			Χ	Χ	Х	Х	
	Strengthen cooperation between health professionals and patients organizations								
3	Facilitate a more timely diagnosis and new methods of diagnosis	3	Χ		Χ				Χ
3	National Action Plan research on Rare Diseases	3		Χ		Χ	Χ		
4	Develop compassionate Programme	2			Χ		Χ		
5	Disease Management for RD (mediators need between stakeholders)	1			Χ				
5	Support development of Regional Alliances in a country	1				Χ			
5	Creation of one national organization representing all regions	1				Χ			
5	Creation of Permanent Regional Commissions of study on RD in each region	1				Χ			
5	Request public health system to finance OMPs as for chronic diseases	1					Χ		
5	Improving nationally the distribution of adequate treatment in hospitals, pharmacies	1					Χ		
5	Create a specialty in genetics within the schools of medicine	1					Χ		
5	New born screening for all rare disorders for which a treatment exists - nationwide	1			Χ				
5	Reform reimbursement of costs for the care of patients with RD	1			Χ				
5	Develop Rare Disorders Awareness, Health care system,insurances	1			Χ				
5	Educate patients organizations to become active and strong actors	1			Χ				
5	Involve patients when writing the patients information for prescribed drugs	1			Χ				
5	Need to improve patients/GP/stakeholders relationships	1			Χ				
5	Address the concern of Rare Diseases at Health Ministry level	1							Χ



SYNTHESIS

- > Themes > 3 X
- > « Orphan » themes
- Discussion



SYNTHESIS

CARE:

EUROPE

clinical trials & Fast track

NATIONAL

>10X KM : OMP database **Existing treatment** - Clinical trials **RESEARCH:** >3X list of molecules abandonned by industry **RESEARCH:** >3X **Epidemiological studies** ⊳RESEARCH: >3X **Dedicated methodology for**

Compassionate Programmes

>2X



ANALYSIS

European Research Networks on RD

- Epidemiological studies
- Clinical trials
- Abandoned products
- ♦ DNA network

European Care Network on RD

- Cooperation between shareholders
 - Standards & Guidelines therapy

EMEA Ind
Pharma
Patients Gyt
(price)

Improve procedures of patient/investigators recruitment

Insurances Physisians
Ind Patients



ANALYSIS BY THEMES

- > Themes > 3 X
- > « Orphan » themes
- Discussion



"ORPHAN IDEAS"

European Economic and Insurance Tool

Identify barriers between research & producers

Create an OMP Economic Committee managed by EMEA

Improve patient / MD / stakeholder relationship



ANALYSIS BY THEMES

- > Themes > 3 X
- > « Orphan » themes
- Discussion




> Your feedback



Example: "Review Clinical trials methodology"

European Research Center on RD

Targets



- Phase I: avoid testing molecules on healthy people
- Phase II: small group
- Skip phase III- Fast track approval

Compassion ate program

Create a
 European
 Task Force
 to reassess
 clinical trials



Example: "Towards supranational OMPs"

Targets



- Incentives : harmonization
- Pricing: indicative price range
- Retailing : blue box
- Convey a
 European
 Harmonizatio
 n Task Force
 to suppress
 the blue box
- Create an OMP
 Economic
 Committee to be managed by EMEA



> Back up



Example: "Epidemiological studies"

European Research Network on RD

Targets



- Explore organization methods tools
- Collect existing data
- Call for ad hoc tenders
- Co-ordinate studies
- European research center



ORGANIZATION

Epidemiological studies

Country 1

Clinical trials

Country 2

European research Network on RD

Data base

Country 5

DNA network

Country 4

Abandoned products

Country 3



Example: "Center of Excellence"

European Care Network on RD

Targets



- Explore organization methods tools
- Collect existing data

Cooperation at a European level

 All group of diagnoses belong to a center



ORGANIZATION

Center of excellence

Country 1

Center of excellence

Country 2

European Care Network on RD

Center of excellence

Country ...

Center of excellence

Country 4

Center of excellence

Country 3

This report was produced by a contractor for Health & Consumer Protection Directorate General and represents the views of the contractor or author. These views have not been adopted or in any way approved by the Commission and do not necessarily represent the view of the Commission or the Directorate General for Health and Consumer Protection. The European Commission does not guarantee the accuracy of the data included in this study, nor does it accept responsibility for any use made thereof.